Clinical trials in Senhora Da Hora

679 clinical trials in Senhora Da Hora, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Senhora Da Hora at a glance

679

clinical trials

Research sites0

Quick filters

679 trials in Senhora Da Hora

Open in trial search

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

Portugal

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:Sanofi Pasteur Inc.

Contact Research Centre

Dermatitis atopic

Recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Colitis ulcerative

Recruiting

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:LY4268989 adipic acid
Sponsor:Eli Lilly & Co.

Contact Research Centre

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Primary progressive multiple sclerosis

Recruiting

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Orelabrutinib
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Psoriatic arthropathy

Recruiting

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic spontaneous urticaria

Recruiting

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Epinephrine
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo

Portugal

Participants:18–64 years
Substances:Bevacizumab
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Senhora Da Hora

What the registry says about research in the country

01 Neurology & Mental Health

Innovative research focusing on Alzheimer's disease and associated conditions, including studies on psychosis treatment and cognitive decline prevention. Multiple trials exploring migraine prevention with novel therapeutic approaches.

Alzheimer's Disease Management
Migraine Prevention
Multiple Sclerosis Treatment

Studies are evaluating both symptomatic relief and disease modification strategies.

02 Oncology

Comprehensive research in breast cancer treatments, particularly focusing on HR+/HER2- variants and innovative combination therapies. Advanced studies in non-small cell lung cancer exploring new treatment paradigms.

Breast Cancer Therapeutics
Lung Cancer Treatment
Head and Neck Cancer

Trials emphasize targeted therapies and immunotherapy approaches.

03 Respiratory Medicine

Groundbreaking research in severe asthma management and chronic rhinosinusitis. Studies evaluating new treatments for COPD with focus on long-term safety and efficacy.

Asthma Management
COPD Treatment
Rhinosinusitis Therapy

Emphasis on innovative inhaler combinations and targeted biological treatments.

Back to Portugal All countries